02.28.14
ArtVentive Medical Group Inc. has added John Rappe to its executive team as senior vice president of Global Marketing and North American sales.
“The company’s momentum requires global industry expertise to support the tremendous demand we are projecting,” CEO Jim Graham said. “With 20 years of success in sales, marketing and branding within the medical industry, John Rappe is an important addition to the ArtVentive Medical team.”
Rappe will lead global marketing and the North American launch of the company’s EOS Peripheral Vascular Occlusion system, a self-expandable catheter-based device that facilitates immediate, reliable and permanent occlusion of body lumens. The company received the European CE Mark certification in 2013 and is commencing shipping to its expanding European distribution network as it prepares the foundation to launch into the United States and other international markets following regulatory approval.
“ArtVentive is poised to become a leader in the embolization market,” Rappe said. “The clinical benefits of the ArtVentive EOS device offer patients an alternative to major surgery. This is an exciting time to be joining the company.”
Rappe most recently worked for Boston Scientific Corporationfor eight years. Prior to that, he was vice president of sales and marketing for Young Innovations Inc., a global manufacturer and provider of preventative dental consumables and diagnostic imaging equipment.
“It is essential that we continue to expand our international management team with experienced professionals such as John in achieving our global corporate goals,” Graham added.
Based in Carlsbad, Calif., ArtVentive Medical Group develops, manufactures and markets endoluminal occlusion devices. The EOS system is catheter-based and self-expandable and facilitates permanent or temporary occlusion of body lumens, a cavity found within the vascular system and organ network within the body. The ArtVentive EOS device targets the global market in several major clinical areas, including peripheral, neurological vascular, women’s health (minimally invasive contraceptive and birth control), interventional cardiology, pulmonary and oncology.
“The company’s momentum requires global industry expertise to support the tremendous demand we are projecting,” CEO Jim Graham said. “With 20 years of success in sales, marketing and branding within the medical industry, John Rappe is an important addition to the ArtVentive Medical team.”
Rappe will lead global marketing and the North American launch of the company’s EOS Peripheral Vascular Occlusion system, a self-expandable catheter-based device that facilitates immediate, reliable and permanent occlusion of body lumens. The company received the European CE Mark certification in 2013 and is commencing shipping to its expanding European distribution network as it prepares the foundation to launch into the United States and other international markets following regulatory approval.
“ArtVentive is poised to become a leader in the embolization market,” Rappe said. “The clinical benefits of the ArtVentive EOS device offer patients an alternative to major surgery. This is an exciting time to be joining the company.”
Rappe most recently worked for Boston Scientific Corporationfor eight years. Prior to that, he was vice president of sales and marketing for Young Innovations Inc., a global manufacturer and provider of preventative dental consumables and diagnostic imaging equipment.
“It is essential that we continue to expand our international management team with experienced professionals such as John in achieving our global corporate goals,” Graham added.
Based in Carlsbad, Calif., ArtVentive Medical Group develops, manufactures and markets endoluminal occlusion devices. The EOS system is catheter-based and self-expandable and facilitates permanent or temporary occlusion of body lumens, a cavity found within the vascular system and organ network within the body. The ArtVentive EOS device targets the global market in several major clinical areas, including peripheral, neurological vascular, women’s health (minimally invasive contraceptive and birth control), interventional cardiology, pulmonary and oncology.